Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT

Priscila Da Silva Figueiredo Celestino Gomes1,2, Isaure Chauvot De Beauchêne1, Nicolas Panel1

  • 1Laboratoire de Biologie et Pharmacologie Appliquée (LBPA), ENS Cachan, CNRS, Université, Paris-Saclay, 94235 Cachan, France.

Plos One
|July 29, 2016
PubMed

Insights

Tyrosine kinase inhibitors like Imatinib can be affected by mutations in KIT and CSF-1R receptors. Specific mutations, such as D802V in CSF-1R and D816V in KIT, cause resistance to Imatinib treatment.

Area of Science:

  • Molecular biology
  • Biochemistry
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs), including CSF-1R and KIT, are crucial for signal transduction.
  • Gain-of-function mutations in RTKs can lead to constitutive activation, driving cancer and proliferative diseases.
  • Mutations alter RTK sensitivity to tyrosine kinase inhibitors, impacting therapeutic efficacy.

Purpose of the Study:

  • To investigate the impact of specific KIT and CSF-1R mutations on Imatinib binding affinity and drug sensitivity.
  • To elucidate the molecular mechanisms underlying mutation-induced alterations in drug response.

Main Methods:

  • Molecular dynamics simulations and energy calculations of Imatinib•target complexes.
  • Analysis of Imatinib binding free energy to native and mutated KIT and CSF-1R.
  • Experimental measurement of KIT receptor phosphorylation inhibition to assess drug sensitivity.

Main Results:

  • A strong correlation exists between calculated binding free energy and experimentally determined Imatinib sensitivity.
  • Electrostatic interactions significantly influence Imatinib binding energy to RTKs.
  • CSF-1R D802V and KIT D816V mutations most severely decrease Imatinib sensitivity.
  • The juxtamembrane region (JMR) plays a minor role in Imatinib binding.

Conclusions:

  • Binding free energy calculations accurately predict drug sensitivity changes due to RTK mutations.
  • Electrostatic forces are key determinants of Imatinib efficacy against mutated RTKs.
  • Understanding these mutation-drug interactions can inform the development of more effective cancer therapies.